A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp… - Blood, The Journal …, 2015 - ashpublications.org
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
[HTML][HTML] A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - Blood, 2015 - Elsevier
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
A Rothe, S Sasse, MS Topp, DA Eichenauer… - Blood, 2015 - europepmc.org
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - …, 2015 - pubmed.ncbi.nlm.nih.gov
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
[PDF][PDF] A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - 2015 - Citeseer
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb®) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
[PDF][PDF] A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - 2015 - academia.edu
AFM13 was also active in brentuximab vedotin–refractory patients. In 13 patients who
received doses of‡ 1.5 mg/kg AFM13, the overall response rate was 23% and the disease …
received doses of‡ 1.5 mg/kg AFM13, the overall response rate was 23% and the disease …
[HTML][HTML] A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - Blood, 2015 - ncbi.nlm.nih.gov
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
[PDF][PDF] A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - 2015 - Citeseer
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb®) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
A Rothe, S Sasse, MS Topp, DA Eichenauer… - Blood, 2015 - europepmc.org
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp, DA Eichenauer… - Blood, 2015 - kups.ub.uni-koeln.de
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …